Celltrion Chairman Seo Jung-jin said on Nov. 18, "The necessary clinical trials for the COVID-19 antibody treatment will be terminated within this month and we will start the emergency use approval process next month."
He made the announcement at his visit to the Korea Bio-industry event held at Yonsei University Global Campus in Songdo, Yeonsu-gu, Incheon.
Chairman Suh said, "We plan to organize all clinical data by the end of this year and go through conditional approval by the Ministry of Food and Drug Safety."
He said, "We will do our best to help the people return to their daily lives at the earliest possible time. We are very interested in how much other countries as well as Korea can secure for the COVID-19 antibody treatment that we develop."
The company announced its investment plans, including the establishment of a research center. "We will invest 500 billion won ($450 million) in the expansion of factories for the production of multiple varieties and the establishment of a stable supply system and the construction of a large research center in Songdo,” he added.